Grading of well-differentiated pancreatic Neuroendocrine tumors is improved by the inclusion of both ki67 Proliferative index and mitotic rate

American Journal of Surgical Pathology

Volumn 37, Issue 11, 2013, Pages 1671-1677

  McCall, Chad M ^a   Shi, Chanjuan ^b   Cornish, Toby C ^a   Klimstra, David S ^c   Tang, Laura H ^c   Basturk, Olca ^c   Mun, Liew Jun ^a   Ellison, Trevor A ^d   Wolfgang, Christopher L ^d   Choti, Michael A ^d   Schulick, Richard D ^e   Edil, Barish H ^e   Hruban, Ralph H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

endocrine neoplasm; gastroenteropancreatic neuroendocrine tumor; Ki67; neuroendocrine tumor; pancreas; pancreatic cancer; pancreatic endocrine neoplasm islet cell tumor; pancreatic neuroendocrine tumor

Indexed keywords

KI 67 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY; CANCER GRADING; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METASTASIS; MIDDLE AGED; MITOSIS INDEX; MORTALITY; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84886401222     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000089     Document Type: Article

References (22)

1. Klimstra DS, Arnold R, Capella C, et al. Neuroendocrine neoplasms of the pancreas. In: Bosman F, Carneiro F, Hruban RH, Theise N, eds. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press; 2010:322-326.
2. Klo ppel G, Rindi G, Anlauf M, et al. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007;451(suppl 1):S9-S27.
3. Verbeke CS. Endocrine tumours of the pancreas. Histopathology. 2010;56:669-682.
4. Capelli P, Martignoni G, Pedica F, et al. Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med. 2009;133:350-364.
5. La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40:30-40.
6. Ekeblad S, Skogseid B, Dunder K, et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798-7803.
7. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34:300-313.
8. Tang LH, Gonen M, Hedvat C, et al. Objective quantification of the ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012;36:1761-1770.
9. Goodell PP, Krasinskas AM, Davison JM, et al. Comparison of methods for proliferative index analysis for grading pancreatic welldifferentiated neuroendocrine tumors. Am J Clin Pathol. 2012; 137:576-582.
10. Couvelard A, Deschamps L, Ravaud P, et al. Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol. 2009;22:273-281.
11. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35:853-860.
12. Rindi G, Klo ppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401.
13. Wang S, Saboorian MH, Frenkel EP, et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-Assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol. 2001;116: 495-503.
14. Minot DM, Kipp BR, Root RM, et al. Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: development of a standardized scoring method that correlates with FISH. Am J Clin Pathol. 2009;132:133-138.
15. Dhall D, Frishberg DP, Galliano G, et al. Interobserver variability in assessing Ki-67 proliferative index in gastrointestinal welldifferentiated neuroendocrine neoplasms. Mod Pathol. 2009; 22:116A.
16. Ellison TA, Wolfgang CL, Shi C, et al. A single institutions 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg. 2013. [Epub ahead of print].
17. Lowe K, Khithani A, Liu E, et al. Ki-67 labeling: a more sensitive indicator of malignant phenotype than mitotic count or tumor size? J Surg Oncol. 2012;106:724-727.
18. Hamilton NA, Liu T-C, Cavatiao A, et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery. 2012;152:107-113.
19. Kim Y-J, Ketter R, Steudel W-I, et al. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol. 2007;128:118-125.
20. Tapia C, Kutzner H, Mentzel T, et al. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;30:83-89.
21. Ladstein RG, Bachmann IM, Straume O, et al. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 2010;10:140.
22. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-Associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.